Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

An article about the importance of PSA testing for early detection and treatment of prostate cancer ...

A remarkable scientific advancement could transform how prostate cancer is detected in men around the world. Researchers have developed a groundbreaking urine test that offers significant advantages ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital, and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...